JP2020502268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502268A5 JP2020502268A5 JP2019551913A JP2019551913A JP2020502268A5 JP 2020502268 A5 JP2020502268 A5 JP 2020502268A5 JP 2019551913 A JP2019551913 A JP 2019551913A JP 2019551913 A JP2019551913 A JP 2019551913A JP 2020502268 A5 JP2020502268 A5 JP 2020502268A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- heterocyclyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 44
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000000623 heterocyclic group Chemical group 0.000 claims 24
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000005842 heteroatom Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 16
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 229910052717 sulfur Inorganic materials 0.000 claims 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433470P | 2016-12-13 | 2016-12-13 | |
| US62/433,470 | 2016-12-13 | ||
| PCT/US2017/065665 WO2018111787A1 (en) | 2016-12-13 | 2017-12-12 | Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of il-12, il-23, and/or ifn alpha responses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502268A JP2020502268A (ja) | 2020-01-23 |
| JP2020502268A5 true JP2020502268A5 (cg-RX-API-DMAC7.html) | 2021-01-07 |
| JP7046092B2 JP7046092B2 (ja) | 2022-04-01 |
Family
ID=60888685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551913A Active JP7046092B2 (ja) | 2016-12-13 | 2017-12-12 | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤としてのホスフィンオキシドアルキルアミド置換ヘテロアリール化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10294256B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3555111B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7046092B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102602558B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110267964B (cg-RX-API-DMAC7.html) |
| AR (1) | AR110351A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2907008T3 (cg-RX-API-DMAC7.html) |
| MA (1) | MA48602A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201827423A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018111787A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102702228B1 (ko) | 2017-11-21 | 2024-09-02 | 브리스톨-마이어스 스큅 컴퍼니 | 술폰 피리딘 알킬 아미드-치환된 헤테로아릴 화합물 |
| UY38144A (es) | 2018-03-12 | 2019-10-31 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa |
| EP3768667B1 (en) * | 2018-03-22 | 2023-04-12 | Bristol-Myers Squibb Company | Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses |
| CN114787154A (zh) * | 2020-01-19 | 2022-07-22 | 苏州科睿思制药有限公司 | 一种Deucravacitinib的晶型及其制备方法和用途 |
| CN120904157A (zh) | 2020-12-22 | 2025-11-07 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| JP2024510274A (ja) | 2021-03-16 | 2024-03-06 | アンルイ バイオメディカル テクノロジー （グァンヂョウ） カンパニー リミテッド | アミノヘテロアリール化合物および組成物 |
| CN115724830A (zh) * | 2021-08-31 | 2023-03-03 | 浙江文达医药科技有限公司 | 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法 |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007501775A (ja) * | 2003-08-07 | 2007-02-01 | ノバルティス アクチエンゲゼルシャフト | 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤 |
| PL2300013T5 (pl) * | 2008-05-21 | 2025-04-28 | Takeda Pharmaceutical Company Limited | Pochodne fosforu jako inhibitor kinazy |
| TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| CN104125947A (zh) * | 2011-12-21 | 2014-10-29 | 生物区欧洲有限公司 | 杂环脲化合物 |
| JP6469567B2 (ja) * | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| TWI620737B (zh) * | 2012-11-08 | 2018-04-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| PE20150944A1 (es) | 2012-11-08 | 2015-06-20 | Bristol Myers Squibb Co | COMPUESTOS HETEROCICLICOS SUSTITUIDOS CON AMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE INTERLEUCINA 12(IL-12), INTERLEUCINA 23 (IL-23) Y/O INTERFERON ALFA (IFN(alfa)) |
| WO2014181287A1 (en) * | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| AR094537A1 (es) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| EP2947460A1 (en) * | 2014-05-22 | 2015-11-25 | Medizinische Universität Wien | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists |
-
2017
- 2017-12-12 JP JP2019551913A patent/JP7046092B2/ja active Active
- 2017-12-12 AR ARP170103473A patent/AR110351A1/es unknown
- 2017-12-12 KR KR1020197019993A patent/KR102602558B1/ko active Active
- 2017-12-12 WO PCT/US2017/065665 patent/WO2018111787A1/en not_active Ceased
- 2017-12-12 TW TW106143529A patent/TW201827423A/zh unknown
- 2017-12-12 US US15/838,434 patent/US10294256B2/en active Active
- 2017-12-12 CN CN201780086194.3A patent/CN110267964B/zh active Active
- 2017-12-12 EP EP17822919.1A patent/EP3555111B1/en active Active
- 2017-12-12 ES ES17822919T patent/ES2907008T3/es active Active
- 2017-12-12 MA MA048602A patent/MA48602A/fr unknown